P2Et for COVID-19: real-time analysis

Download Image

Post

c19early.org

P2Et for COVID-19

1 study with 91 patients

Serious outcome risk

P2Et

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 P2Et studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−114%

Mortality (1)−114%

Hospitalization (1)23%

RCTs (1)−114%

Late (1)−114%

00.511.5+

← P2Et
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

P2Et is an oral phytomedicine, an extract from Caesalpinia spinosa, with potential anti-inflammatory and antiviral effects.


Sep 8 2022	Urueña et al., Frontiers in Medicine, doi:10.3389/fmed.2022.991873	Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et)
Sep 8 2022	24% lower ICU admission (p=0.76) and 23% shorter hospitalization (p=0.12). RCT 91 hospitalized COVID-19 patients in Colombia showing no significant differences in clinical outcomes with P2Et treatment. P2Et treatment was associated with reduced pro-inflammatory cytokines (G-CSF, IL-5, IL-18) and increased NK cel..